Johnson & Johnson is ranked second among the most undervalued pharma stocks to buy now. The company reported promising Phase 1 results for pasritamig, a drug targeting metastatic castration-resistant prostate cancer with low side effects. Other advances include applications for treating pediatric Crohn’s disease and AML, as well as launching a new contact lens.

Johnson & Johnson plans to invest $55 billion in expanding U.S.-based manufacturing and R&D. While a potential investment, AI stocks may offer greater upside with less risk. For an undervalued AI stock benefiting from tariffs and onshoring trends, check out the free report on the best short-term AI stock.

Overall, Johnson & Johnson continues to make strides in healthcare innovation with promising drug developments and strategic investments in manufacturing and research.

Read more at Yahoo Finance: Johnson & Johnson (JNJ)’s Pasritamig Shows Breakthrough Promise in Prostate Cancer